RIMADYL SOLUTION

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

CARPROFEN

Tilgængelig fra:

ZOETIS CANADA INC

Dosering:

50MG

Lægemiddelform:

SOLUTION

Sammensætning:

CARPROFEN 50MG

Indgivelsesvej:

SUBCUTANEOUS

Enheder i pakken:

20ML

Recept type:

Prescription

Terapeutisk gruppe:

DOGS

Produkt oversigt:

Active ingredient group (AIG) number: 0137034004

Autorisation status:

APPROVED

Autorisation dato:

2004-07-08

Indlægsseddel

DIN 02255693
_CARPROFEN INJECTABLE SOLUTION _
VETERINARY USE ONLY
Non-steroidal anti-inflammatory
For subcutaneous use in dogs only.
DESCRIPTION:
Rimadyl
injectable
solution
is
a
sterile
solution
containing
carprofen,
a
non-steroidal
anti-
inflammatory drug (NSAID) of the propionic acid class
that includes ibuprofen, naproxen, and ketoprofen. The
chemical name for carprofen, a substituted carbazole, is
(±)-6-chloro-α-
methylcarbazole-2-acetic
acid.
The
empirical formula is C
15
H
12
NO
2
CI and molecular weight
273.72. The chemical structure of carprofen is:
Each
mL
of
Rimadyl
injectable
solution
contains
50.0 mg of carprofen as the medicinal ingredient and
10.0 mg of benzyl alcohol as the preservative.
CLINICAL PHARMACOLOGY: Carprofen is a non-
narcotic,
non-steroidal
anti-inflammatory
agent
with characteristic analgesic and antipyretic activity
approximately equipotent to indomethacin in animal
models.
1
The mechanism of action of carprofen, like that of
other NSAIDs, is believed to be associated with the
inhibition of cyclooxygenase activity. Two unique
cyclooxygenases have been described in mammals.
2
The constitutive cyclooxygenase, COX-1, synthesizes
prostaglandins necessary for normal gastrointestinal
and renal function. The inducible cyclooxygenase,
COX-2,
generates
prostaglandins
involved
in
inflammation. Inhibition of COX-1 is thought to be
associated with gastrointestinal and renal toxicity
while inhibition of COX-2 provides anti-inflammatory
activity. The
specificity
of
a
particular NSAID
for
COX-2
versus
COX-1
may
vary
from
species
to
species.
3
In an _in vitro _study using canine cell cultures,
carprofen
demonstrated
selective
inhibition
of
COX-2 versus COX-1.
4
Clinical relevance of these data
has not been shown. Carprofen has also been shown to
inhibit the release of several prostaglandins in two
inflammatory cell systems: rat polymorphonuclear
leukocytes (PMN) and human rheumatoid synovial
cells, indicating inhibition of acute (PMN system) and
chronic (synovial cell system) inflammatory reactio